Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Fischbach, F; Hass, P; Schindele, D; Genseke, P; Geisendorf, L; Stehning, C; Schostak, M; Brunner, T; Pech, M; Fischbach, K.
MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
Eur Radiol. 2020; 30(4):2072-2081
Doi: 10.1007/s00330-019-06505-0
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: The aim of the study was to establish the setup and workflow for delivering focal MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer (PCA) and to assess patient comfort and safety aspects of MRI-guided single-fraction HDR. METHODS: Patients with histologically proven focal low- to intermediate-risk PCA with a single PIRADS 4/5 lesion were treated with percutaneous interstitial HDR brachytherapy in a single fraction with a minimum dose for the gross tumor volume of 20 Gy while sparing the organ at risk (OAR). Using a 3T-MRI, brachytherapy catheters were placed transgluteal in freehand technique. No antibiotic therapy or general analgesics were administered. Patient data, procedure time, patient discomfort, and complications were recorded. Quarterly PSA controls, biannual follow-up imaging, and annual re-biopsy were planned. RESULTS: So far, 9 patients were successfully treated and followed for 6 months. Mean intervention time was 34 min. Using the VAS scale, the pain reported for the intervention ranged from 2 to 3. Short-term follow-up showed no acute genitourinary or gastrointestinal toxicity so far. None of the patients displayed signs of infection. PSA levels in all patients decreased significantly. On follow up no residual PCA was detected treated region so far. PSA levels in all patients decreased significantly. On follow-up, no residual PCA was detected so far. CONCLUSIONS: MR-guided single-fraction focal HDR brachytherapy for localized PCA is feasible as well as safe for the individual patient. Catheters can be placed accurately and maximum therapeutic dose distribution can be restricted to the tumor. Countersigning the minimally invasive character of the procedure, no general anesthesia or antibiosis is necessary. KEY POINTS: • MR-guided focal HDR brachytherapy allows an accurate placement of catheters with maximum therapeutic dose distribution restricted to the tumor. • No major anesthesia or antibiosis is necessary emphasizing the minimal invasive character of the procedure. • Patients with low- and intermediate-risk prostate carcinoma in particular may benefit to halt disease progression whereas treatment-related morbidity is reduced compared with radical therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Biomarkers, Tumor - metabolism
- Biopsy - administration & dosage
- Brachytherapy - methods
- Feasibility Studies - administration & dosage
- Humans - administration & dosage
- Magnetic Resonance Imaging - methods
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Staging - administration & dosage
- Prostate-Specific Antigen - metabolism
- Prostatic Neoplasms - metabolism, pathology, radiotherapy
- Radiotherapy Dosage - administration & dosage
- Find related publications in this database (Keywords)
- Prostate cancer
- Targeted radiation therapy
- Brachytherapy
- Magnetic resonance imaging
- interventional